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OBJECTIVE: We used a large, employer-sponsored, administra-
tive claims database of enrollees using second generation antip-
sychotics (SGAs) to address two study objectives: 1) describe
patterns of SGA utilization by metabolic proﬁle (MP) and poly-
therapy, and 2) examine the inﬂuences of MP and SGA poly-
therapy on hospitalization. METHODS: Using descriptive and
logistic regression analyses, we examined patterns of SGA poly-
therapy by MP, focusing on SGA use patterns and their associa-
tion with hospitalization. MP status was categorized as low
(aripiprazole, ziprasidone), moderate (risperidone, quetiapine),
and high (olanzapine). Polytherapy of two or more SGAs was
deﬁned as long-term (i.e., augmentation for90 days) and short-
term (i.e., switching for <90 days). We controlled for sociodemo-
graphics, payor source, comorbidities, concurrent clozapine and
typical use, and drug burden. RESULTS: On average, individuals
received 10.2 SGA scripts annually; 23.8% used low, 70.2% used
moderate, and 22.8% used high MP SGAs. Second generation
antipsychotics polytherapy occurred in 9.6% of all SGA users
(7.3% in low MP, 8.4% in moderate MP, and 7.3% in high MP
SGA users). Switching accounted for 77.4% of all polytherapy.
Relative to high MP users, moderate MP users were slightly more
likely to be hospitalized (moderate MP OR = 1.2 [p < 0.0001]).
Low MP use was not signiﬁcantly different from high MP use
with respect to hospitalization. Relative to monotherapy SGA
users, polytherapy users had hospitalization odds of 1.9
(p < 0.0001). Other positive signiﬁcant covariates included diag-
noses of schizophrenia, bipolar disorder, depression, substance
use disorders, obesity, increasing drug burden and atypical antip-
sychotic exposure. Clozapine use was negatively associated with
all hospitalizations. Similar ﬁndings were found for psychiatric
hospitalizations. CONCLUSION: Polytherapy and moderate
MP SGAs are associated with higher risk of hospitalization com-
pared to high MP SGAs and monotherapy use. These ﬁndings
suggest the need for prudent selection of SGAs taking into
account patients’ comorbidities and pill burden.
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EFFECTS OF DIRECT-TO-CONSUMER ADVERTISING AND
DETAILING SPENDING ON ANTIDEPRESSANT SWITCH AND
TREATMENT COMPLETION
Chen SY, Hansen R, Maciejewski ML
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVE: Antidepressant discontinuation is a common
problem in treating major depressive disorder (MDD). We exam-
ined the effects of antidepressant-related direct-to-consumer
advertising (DTCA) and detail spending on medication switch-
ing, acute phase completion, and continuation phase completion
among antidepressant users newly diagnosed with MDD.
METHODS: A retrospective cohort study of medical and pre-
scription claims from a large national health plan afﬁliated with
i3 Innovus from 2000 to 2004 was conducted. A total of 5010
individuals with MDD were identiﬁed. Antidepressant switch,
acute phase completion, and continuation completion were
determined by prescription reﬁll records. Logistic regressions
were run with DTCA and detailing spending variables as main
explanatory variables. RESULTS: In the switch model, own
product detailing spending was negatively associated with the
likelihood of switching (OR = 0.61, 95% CI: 0.53–0.69). Own
product detail spending was also positively associated with
acute phase antidepressant completion (P < 0.05). Other pro-
duct DTCA was positively associated with continuation phase
completion. CONCLUSION: Pharmaceutical spending on
physician detail appears to impact antidepressant switching
and completion of acute phase treatment by patients, while
DTCA spending appears to have its greatest impact on success-
ful completion of the continuation phase of antidepressant
treatment.
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OBJECTIVE: Schizophrenia is a serious public health concern
that affects about 1% of people and poses an increasing burden
on societies all over the world. There is a growing recognition
that schizophrenia associates with an increased risk of prema-
ture death. However, little is known about the prevalence of
medical disorders among persons with schizophrenia. Our aim
is to assess the frequency and characteristics of medical disor-
ders among patients with schizophrenia in Spain. METHODS:
From the 2000–2004 National Hospital Discharge Register,
records for all patients 15 yr with schizophrenia were
retrieved. This ofﬁcial database is representative of the national
population and contains information on each episode of patient
care, with the clinical information coded in the ICD-9-CM
format. Physical disorders were deﬁned using their speciﬁc
ICD-9-CM block codes. A validated Charlson’s index was also
employed. RESULTS: Of the 105,152 entries registered, a total
of 60,912 patients (mean age 43 yr; 64% men) were identiﬁed
and eligible for analysis. About 50% of patients had associated
at least one ICD-9-CM physical disorder and 21% had associ-
ated at least one physical disorder of clinical relevance accord-
ing to Charlson’s index. Concerning speciﬁc physical conditions
our data show that endocrine, cardiovascular, respiratory and
digestive disorders were the most common appearing in 13.9%,
12% and 11% of patients respectively. Additionally, 11.5%
and 8.8% of patients had an associated diagnosis of drug and
alcohol addiction. About 38.3% of patients were hospitalised
because a physical disorder. Mortality was signiﬁcantly higher
in this speciﬁc group of patients (5.3% vs. 0.2%, P < 0.001).
CONCLUSION: Physical disorders are frequent and account
for a high number of hospitalisations and associated mortality
in schizophrenia. These ﬁndings have implications for a wide
variety of concerned parties, settings of care and organizational
systems and might provide a health care policy perspective on
interventions designed to control physical health in this popu-
lation.
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THE CHANGE OF PRICES AND EXPENDITURES OFTHE
ORIGINAL AND GENERIC DRUGS OF FLUOXETINE—
A LONGITUDINAL ANALYSIS ON REIMBURSEMENT
DATABASE OFTHE NATIONAL HEALTH INSURANCE
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OBJECTIVE: To investigate the change of prices and expenditure
of the original and generic ﬂuoxetine in Taiwan. METHODS:
The uses of ﬂuoxetine between 1997–2004 were initially selected
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